NCT03132467已完成早期 1 期
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
适应症
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Feasibility of Enrolling 15 Patients Within 2 Years
研究概览
简要总结
This early phase I trial studies the side effects of durvalumab and tremelimumab before surgery in treating patients with hormone receptor positive, HER2 negative stage II-III breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the feasibility of enrolling patients with hormone receptor positive (HR+)/human epidermal growth factor receptor negative (HER2-) breast cancer onto a trial evaluating investigational agents prior to initiating standard neoadjuvant chemotherapy.
II. To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2- breast cancer.
SECONDARY OBJECTIVES:
I. To assess immunologic/molecular responses to tremelimumab and durvalumab in patients with HR+/HER2- breast cancer who receive the combination therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent and any locally-required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA]) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Hormone receptor positive (defined as estrogen receptor [ER] and/or progesterone receptor [PR] positive), HER2 negative breast cancer that is clinically staged II-III with no known metastatic disease. ER and/or PR defined as positive if expression > 10% by immunohistochemistry (IHC). HER2 negative or non-amplified as determined by the current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) criteria which are as follows: HER2 testing by immunohistochemistry (IHC) as 0 or 1+. If HER2 is 2+, ISH (in situ hybridization) must be performed. HER2 is positive if: IHC 3+ based on circumferential membrane staining that is complete, intense ISH positive based on: 1) Single-probe average HER2 copy number >= 6.0 signals/cell, 2) Dual-probe HER2/CEP17 ratio >= 2.0; c,e with an average HER2 copy number >= 4.0 signals/cell, 3) Dual-probe HER2/CEP17 ratio >= 2.0; c,e with an average HER2 copy number < 4.0 signals/cell, 4) Dual-probe HER2/CEP17 ratio < 2.0; c,e with an average HER2 copy number >= 6.0 signals/cell
- •Chemotherapy is planned for the patient in the neoadjuvant setting
- •Hemoglobin >= 9.0 g/dL
- •Absolute neutrophil count (ANC) >=1.5 x 10^9/L (>= 1500 per mm^3)
- •Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3)
- •Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not apply to subjects with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only upon treating physician, principal investigators (PI) or co-PIs approval
- •Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =< 5 x ULN
- •Creatinine clearance (CL) > 40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance
- •Female subjects must either be of non-reproductive potential (i.e., post-menopausal by history: >= 60 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative urine pregnancy test upon study entry
- •Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
排除标准
- •Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •Participation in another clinical study with an investigational product during the last 1 month prior to initiation of therapy
- •Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab
- •History of another primary malignancy except for:
- •Malignancy treated with curative intent and with no known active disease >= 5 years before the first dose of study drug and of low potential risk for recurrence
- •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- •Adequately treated carcinoma in situ without evidence of disease e.g., cervical cancer in situ
- •Has received therapy for this current diagnosis of breast cancer including endocrine therapy or chemotherapy
- •A single QT interval corrected for heart rate (QTc) >= 470 ms. If an electrocardiogram (ECG) is interpreted to be a prolonged QT interval, 2 additional ECGs will be obtained and the PI will then evaluate all three ECGs and determine whether the patient should be excluded. Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia's correction
- •Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid
- •Active or prior documented autoimmune disease within the past 2 years
- •NOTE: Subjects with vitiligo, Graves disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
- •Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- •History of primary immunodeficiency
- •History of allogeneic organ transplant
- •History of hypersensitivity to durvalumab or tremelimumab or any excipient
- •History of hypersensitivity to the combination or comparator agent (if applicable)
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any subject known to have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
- •Known history of previous clinical diagnosis of tuberculosis
- •History of leptomeningeal carcinomatosis
- •Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab or tremelimumab
- •Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •Subjects with uncontrolled seizures
结局指标
主要结局
Feasibility of Enrolling 15 Patients Within 2 Years
时间窗: Up to 2 years
Feasibility established if all 15 patients enroll within 12 months of starting the study. The start date for measuring feasibility will be the date the first patient is screened.
Safety and Tolerability of Tremelimumab Plus Durvalumab in Participants With HR+/HER2 Neg Breast Cancer.
时间窗: 2 months
To evaluate the safety and tolerability of tremelimumab plus durvalumab in patients with HR+/HER2 neg breast cancer. Adverse events per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event \[CTCAE\] v4.03.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary VariantInfiltrating Bladder Urothelial Carcinoma, Plasmacytoid VariantInfiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid VariantRenal Pelvis Urothelial CarcinomaStage II Bladder Urothelial Carcinoma AJCC v6 and v7Stage II Renal Pelvis Cancer AJCC v7Stage II Ureter Cancer AJCC v7Stage II Urethral Cancer AJCC v7Stage III Bladder Urothelial Carcinoma AJCC v6 and v7Stage III Renal Pelvis Cancer AJCC v7Stage III Ureter Cancer AJCC v7Stage III Urethral Cancer AJCC v7Stage IV Renal Pelvis Cancer AJCC v7Stage IV Ureter Cancer AJCC v7Stage IV Urethral Cancer AJCC v7Ureter Urothelial CarcinomaUrethral Urothelial CarcinomaHydronephrosisNCT02812420M.D. Anderson Cancer Center54
已完成
1 期
Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaRecurrent GlioblastomaNCT04201873Jonsson Comprehensive Cancer Center46
终止
早期 1 期
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx CancerStage I Oral Cavity Squamous Cell CarcinomaStage I Oropharyngeal Squamous Cell CarcinomaStage II Oral Cavity Squamous Cell CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage III Oral Cavity Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Oral Cavity Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaHuman Papillomavirus InfectionNCT02827838Wake Forest University Health Sciences17
已完成
1 期
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by SurgeryMetastatic Carcinoma in the LiverResectable MassStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7NCT02754856M.D. Anderson Cancer Center24
已完成
2 期
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT04568200Peking Union Medical College Hospital60